脑深部电刺激治疗难治性重性抑郁障碍:刺激靶点的网络荟萃分析
该网络荟萃分析纳入22项试验(15项为假刺激对照),评估不同脑深部电刺激靶点对难治性重性抑郁障碍的疗效。结果显示内侧前脑束刺激在抑郁症状减分上最优,应答率86%,高于胼胝体下扣带回或内囊前肢刺激;前额皮质吻侧延伸 remission 率最高(60%)但无统计学显著性。
要点
- 内侧前脑束刺激在减轻抑郁症状上优于胼胝体下扣带回和腹侧囊/腹侧纹状体刺激。
- 内侧前脑束刺激的应答率为86%,高于胼胝体下扣带回或内囊前肢刺激。
- 前额皮质吻侧延伸 remission 率60%最高,但与其他靶点比较无统计学显著性。
核心结论
- 内侧前脑束作为难治性抑郁的脑深部电刺激靶点有前景,可能与其参与介导抑郁的中皮质和中脑边缘通路有关。
- 仍需直接比较不同脑区刺激的额外试验来确定内侧前脑束是否为最佳神经刺激靶点。
研究设计与样本
- 系统文献回顾与网络荟萃分析,纳入截至2022年1月发表的文献。
- 共分析22项试验,其中15项为假刺激对照研究。
主要发现
- 与胼胝体下扣带回和腹侧囊/腹侧纹状体刺激相比,内侧前脑束刺激与抑郁症状最大程度减轻相关。
- 内侧前脑束刺激的应答率为86%,高于胼胝体下扣带回或内囊前肢刺激。
- 前额皮质吻侧延伸刺激的 remission 率最高(60%),但与其他脑区刺激比较无统计学显著性。
局限性
- 需要额外试验直接比较不同脑区的刺激,才能确立内侧前脑束为最佳神经刺激靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Major depressive disorder is a significant cause of disability, impacting an estimated 193 million individuals worldwide. Forty percent are estimated to have little to no response to standard pharmacological therapies. Deep brain stimulation (DBS) has emerged as a favorable neuromodulation therapy for treatment-resistant depression, but it remains unclear which brain targets are optimal. METHODS: The authors performed a systematic literature review and meta-analysis of articles published through January 2022 to examine the efficacy of DBS targets in reducing depressive symptoms in patients with treatment-resistant depression. The primary outcome was the reduction in depression severity measured by the Montgomery-Asberg Depression Rating Scale and Hamilton Rating Scale for Depression. Secondary outcomes were responder and remission rates. RESULTS: The authors analyzed 22 trials, 15 of which were sham-controlled studies. This network meta-analysis identified that stimulation of the medial forebrain bundle (MFB) was associated with the greatest reduction in depressive symptoms, compared with stimulation of the subcallosal cingulate gyrus (SCG) and ventral capsule/ventral striatum (VC/VS). Stimulation of the MFB also exhibited a higher responder rate (86%) than stimulation of the SCG or anterior limb of the internal capsule. Stimulation of the rostral extension of the prefrontal cortex was associated with the highest remission rate (60%), but this was not statistically significant compared with stimulation of other brain regions. CONCLUSIONS: The MFB shows promise as a DBS target for treatment-resistant depression, possibly a result of its involvement in the mesocortical and mesolimbic pathways mediating depression. However, additional trials directly comparing stimulation of different brain regions are necessary to establish MFB as the optimal neurostimulation target.
引用
- Naik A, Chu T, Gupta R, et al. Deep brain stimulation for treatment-resistant major depressive disorder: a network meta-analysis of stimulation targets. J Neurosurg. 2025. PMID: 40911913. doi:10.3171/2025.4.JNS242393
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。